Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019

Press Release – No. 20 / 2019

Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019

Copenhagen, October 28, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, will host a conference call on November 14, 2019 at 4 PM CET / 10 AM EST following the announcement of results through the third quarter of 2019.

Presenting during the call will be President and Chief Executive Officer Emmanuel Dulac, Senior Vice President and Chief Financial Officer Matt Dallas, and Executive Vice President and Chief Medical and Development Officer Adam Steensberg, with remaining members of corporate management in attendance. The presentation will be followed by a Q&A session. The conference call will be conducted in English, and the dial-in numbers are:

Denmark……………………… +45 32 72 80 42
United Kingdom……….. ….. +44 (0) 844 571 8892
United States…………… ….. +1 631 510 7495
France……………………. ….. +33 (0) 176700794
Netherlands…………….. ….. +31 (0) 207143545

Passcode 3379579

A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/mmc/p/yhu6rmnz, and will be accessible on the Investor section of Zealand’s website (www.zealandpharma.com/investor). Participants are advised to register for the webcast approximately 10 minutes before the scheduled start. A recording of the event and a transcript will be available on the Investor section of Zealand’s website after the call.

For further information, please contact:

Lani Pollworth Morvan, Investor Relations and Communication
+45 50 60 37 78, [email protected]

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

Attachment